PI3K与MEK双重阻断联合放疗在头颈癌中的研究
本研究在两种分子特征不同的人头颈鳞癌细胞系中,于体外和体内探讨了比美替尼与布帕利西联合放疗的效应。结果显示,两种药物单独使用均有效,但二者联合放疗未获得显著额外获益,三联治疗并不优于放疗联合单一有效药物。
要点
- 布帕利西对两种细胞系均有活性,比美替尼对UT-SCC-14毒性更强。
- 两种药物在体外均未改变放射敏感性。
- 三联治疗未优于放疗联合单一有效药物,联合用药未获显著获益。
核心结论
- 两种药物联合放疗未获得显著获益,尽管各药物单独使用均有效。
研究设计与样本
- 使用两种分子特征不同、低传代的人头颈鳞状细胞癌细胞系,在体外和体内研究比美替尼与布帕利西联合放疗的效果。
主要发现
- 布帕利西在体外对两种细胞系均有活性,而比美替尼对UT-SCC-14毒性更强。
- 两种药物在体外均未改变放射敏感性。
- 布帕利西显著抑制UT-SSC-15单独或联合放疗的生长,但对UT-SCC-14无效。
- 比美替尼联合放疗对UT-SCC-14产生显著延迟,且单独及联合放疗均显著缩小UT-SCC-15肿瘤生长。
- 三联治疗不如放疗联合单一有效药物有效。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: In this study we have combined fractionated radiation treatment (RT) with two molecular targeted agents active against key deregulated signaling pathways in head and neck cancer. MATERIALS AND METHODS: We used two molecularly characterized, low passage HNSCC cell lines of differing biological characteristics to study the effects of binimetinib and buparlisib in combination with radiation in vitro and in vivo. RESULTS: Buparlisib was active against both cell lines in vitro whereas binimetinib was more toxic to UT-SCC-14. Neither agent modified radiation sensitivity in vitro. Buparlisib significantly inhibited growth of UT-SSC-15 alone or in combination with RT but was ineffective in UT-SCC-14. Binimetinib did cause a significant delay with RT in UT-SCC-14 and it significantly reduced growth of the UT-SCC-15 tumors both alone and with RT. The tri-modality treatment was not as effective as RT with a single effective agent. CONCLUSIONS: No significant benefit was gained by the combined use of the two agents with RT even though each was efficacious when used alone.
引用
- Blas K, Wilson TG, Tonlaar N, et al. Dual blockade of PI3K and MEK in combination with radiation in head and neck cancer. Clin Transl Radiat Oncol. 2018. PMID: 30014041. doi:10.1016/j.ctro.2018.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。